Qiagen N.V. — Investor Relations & Filings
Qiagen N.V. is a global provider of "Sample to Insight" solutions, offering technologies that transform biological materials into valuable molecular insights. The company develops and markets sample and assay technologies, automated instrumentation, and bioinformatics software for molecular diagnostics, applied testing, academic research, and pharmaceutical development. Its comprehensive portfolio supports the entire workflow from sample collection and preparation of DNA, RNA, and proteins to analysis and interpretation. Key product areas include sample preparation kits, PCR, digital PCR (dPCR), and next-generation sequencing (NGS) solutions, as well as syndromic testing panels for infectious diseases.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 6-K | 2024-11-07 | English | |
| Major Shareholding Notification 2024 | 2024-11-07 | English | |
| QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full-year 2024 adjusted EPS outlook | 2024-11-07 | English | |
| Major Shareholding Notification 2024 | 2024-10-21 | English | |
| Regulatory Filings 2024 | 2024-09-11 | English | |
| 6-K | 2024-09-04 | English |
Browse filings by year
29 years- 2026 12 filings
- 2025 44 filings
- 2024 38 filings
- 2023 25 filings
- 2022 26 filings
- 2021 31 filings
- 2020 58 filings
- 2019 38 filings
- 2018 26 filings
- 2017 32 filings
- 2016 33 filings
- 2015 33 filings
- 2014 26 filings
- 2013 23 filings
- 2012 17 filings
- 2011 18 filings
- 2010 18 filings
- 2009 19 filings
- 2008 8 filings
- 2007 49 filings
- 2006 6 filings
- 2005 11 filings
- 2004 9 filings
- 2003 10 filings
- 2002 12 filings
- 2001 1 filing
- 2000 1 filing
- 1999 1 filing
- 1998 1 filing
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2024
15 filings
| |||||
| 10736795 | 6-K | 2024-11-07 | English | ||
| 10736797 | Major Shareholding Notification 2024 | 2024-11-07 | English | ||
| 2434028 | QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full-year 2024 adjusted EPS outlook | 2024-11-07 | English | ||
| 10736798 | Major Shareholding Notification 2024 | 2024-10-21 | English | ||
| 10736800 | Regulatory Filings 2024 | 2024-09-11 | English | ||
| 10736803 | 6-K | 2024-09-04 | English | ||
| 10736805 | 6-K | 2024-09-03 | English | ||
| 2435247 | QIAGEN N.V. launches non-US offering of net share settled convertible bonds | 2024-09-03 | English | ||
| 2435246 | QIAGEN N.V. launches non-US offering of net share settled convertible bonds | 2024-09-03 | English | ||
| 2154366 | Interim / Quarterly Report 2024 | 2024-08-16 | English | ||
| 10234470 | Half-yearly financial report 2024 | 2024-08-02 | English | ||
| 10736806 | 6-K | 2024-08-01 | English | ||
| 10736809 | 6-K | 2024-08-01 | English | ||
| 10736860 | 6-K | 2024-08-01 | English | ||
| 2435666 | QIAGEN delivers solid performance and exceeds outlook for Q2 2024 | 2024-08-01 | English | ||
Financials
We couldn't load the financials
No data available yet
We have extracted financials for Qiagen N.V., but not for this combination of statement and period. Try a different combination.
Swipe the table to view all periods, or rotate your phone for a wider view.
| Line item | ! |
|---|---|
| Definition not yet available — coming soon. |
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
Qiagen N.V. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/4528/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=4528 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=4528 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=4528 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 4528}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Qiagen N.V. (id: 4528)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.